Pemigatinib

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 246 publications

Management of Nail Toxicities From Fibroblast Growth Factor Receptor Inhibitors.

Management of Nail Toxicities From Fibroblast Growth Factor Receptor Inhibitors.

Journal: Journal of drugs in dermatology : JDD
Published: March 04, 2026

FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies.

FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies.

Journal: Cancers
Published: December 29, 2025

The FGFR1 N546K mutation confers resistance to pemigatinib in MLN-ZMYM2::FGFR1.

The FGFR1 N546K mutation confers resistance to pemigatinib in MLN-ZMYM2::FGFR1.

Journal: Leukemia
Published: December 11, 2025

Acquired FGFR2 mutation leads resistance to pemigatinib in a patient with FGFR2-driven Borrmann type IV gastric cancer.

Acquired FGFR2 mutation leads resistance to pemigatinib in a patient with FGFR2-driven Borrmann type IV gastric cancer.

Journal: Anti-cancer drugs
Published: December 03, 2025

FGFR Aberrations in Solid Tumors: Mechanistic Insights and Clinical Translation of Targeted Therapies.

FGFR Aberrations in Solid Tumors: Mechanistic Insights and Clinical Translation of Targeted Therapies.

Journal: Cancers
Published: November 17, 2025

Phase I results of a multicenter, open-label, dose de-escalation and expansion study of gemcitabine and cisplatin with ivosidenib or pemigatinib for advanced cholangiocarcinoma.

Phase I results of a multicenter, open-label, dose de-escalation and expansion study of gemcitabine and cisplatin with ivosidenib or pemigatinib for advanced cholangiocarcinoma.

Journal: Investigational new drugs
Published: November 12, 2025

VPS33A Promotes Pemigatinib Resistance in Cholangiocarcinoma via Autophagy.

VPS33A Promotes Pemigatinib Resistance in Cholangiocarcinoma via Autophagy.

Journal: Digestive diseases and sciences
Published: November 09, 2025

Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib.

Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib.

Journal: Blood
Published: October 28, 2025

Cholangiocarcinoma - Morphology, Immunohistochemistry, and Genetics.

Cholangiocarcinoma - Morphology, Immunohistochemistry, and Genetics.

Journal: Ceskoslovenska patologie
Published: October 16, 2025

Rare gliomas: standard treatment approaches and new target therapies.

Rare gliomas: standard treatment approaches and new target therapies.

Journal: Current opinion in neurology
Published: September 24, 2025

Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1.

Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1.

Journal: International journal of molecular sciences
Published: September 17, 2025

Perioperative and precision strategies in resectable intrahepatic cholangiocarcinoma.

Perioperative and precision strategies in resectable intrahepatic cholangiocarcinoma.

Journal: Global health & medicine
Published: September 03, 2025
Showing 1-12 of 246

Last Updated: 04/28/2026